Akebia Therapeutics, Inc.
AKBA
$3.25
$0.06472.03%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -95.96% | 126.80% | -13.80% | -133.50% | 52.28% |
| Total Depreciation and Amortization | 0.64% | -97.68% | 44.47% | -0.38% | 0.37% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 71.75% | 21.02% | -30.96% | 322.88% | -36.44% |
| Change in Net Operating Assets | 117.16% | -820.02% | 57.79% | 43.89% | 9.93% |
| Cash from Operations | 264.46% | -204.23% | 33.29% | 33.49% | 48.20% |
| Capital Expenditure | -600.00% | -800.00% | 0.00% | 93.10% | -- |
| Sale of Property, Plant, and Equipment | -100.00% | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -181.82% | 7,800.00% | 0.00% | 93.10% | -- |
| Total Debt Issued | -100.00% | -- | -- | -100.00% | -78.38% |
| Total Debt Repaid | 100.00% | -46,300.00% | -- | 100.00% | 98.98% |
| Issuance of Common Stock | -97.37% | 193.26% | 1,179.31% | 12,364.29% | -99.93% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | -- | 100.00% | -- | 100.00% |
| Cash from Financing | -97.70% | 235.69% | 1,725.43% | -83.99% | -58.65% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -61.08% | 244.45% | 426.21% | -122.97% | -156.53% |